Invitae Hereditary Pancreatic Cancer Panel
Use
The Invitae Hereditary Pancreatic Cancer Panel analyzes genes associated with adult-onset pancreatic cancer predisposition. It aids in confirming clinical diagnosis, predicting disease prognosis, facilitating early symptoms detection, informing family planning, genetic counseling, and clinical trial enrollment. Given the overlap of pancreatic cancer susceptibility conditions, the broad panel approach provides efficient evaluation of various potential genes under one clinical indication. Some targeted genes may relate to other disorders not included in this test.
Special Instructions
This test focuses on heritable germline mutations and is not suitable for detecting somatic mutations in tumor tissue. It allows customization by adding or removing genes based on specific requirements at no extra charge. Alternate specimens like saliva, buccal swab, and genomic DNA are also accepted, accommodating various collection methods.
Limitations
This assay does not detect somatic mutations and is specific to germline mutations. Variants outside clinically significant regions are not analyzed. Certain structural rearrangements, single-exon copy number events, or complex sequence variants may not be detected. Analytical coverage excludes promoter regions, non-coding exons/terms unless explicitly stated.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
Purple-top EDTA tube (K2EDTA or K3EDTA)